ArticleInfection and drug resistance2026
Low Prevalence of Integrase Inhibitor Resistance Following Treatment Failure: A Real-World Analysis from Hunan Province, China.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: With the global advancement of Global Combination Antiretroviral Therapy (cART) into the Integrase strand-transfer inhibitors (INSTIs) era, Human immunodeficiency virus (HIV) RNA virological suppression rates and treatment persistence have significantly improved due to the high efficacy and favorable tolerability of these agents. However, resistance to INSTIs, triggered by treatment failure for various reasons, is gradually increasing. The aim of this study was to assess the epidemiological characteristics, transmission dynamics of HIV INSTIs resistance mutations and their early warning value for regional prevention and control. Patients and Methods: Plasma samples were collected from patients in Hunan Province from January 2019 to December 2024, who were receiving INSTIs for at least 6 months, and experienced virological failure (viral load ≥1000 copies/mL). HIV-1 RNA quantitation and genotypic drug resistance testing were performed. Categorical variables were compared using Chi-square or Fisher's exact test. Statistical analyses were performed using R 4.5.3. Results: 125 participants were enrolled, 72.00% were male, with a mean age of 51.84 ± 15.99 years. 60.00% had a CD4 count below 300 cells/μL and 41.60% had a viral load between 10,000-<100,000 copies/mL. Drug resistance mutations (DRMs) were detected in 5 patients (4.00%, 95% CI: 1.31-9.09%). The mutation rate was 1.64% (1/61, 95% CI: 0.04-8.80%) in the BIC-based regimens group and 6.78% (4/59, 95% CI: 1.88-16.46%) in the DTG-based regimens group. There was no statistically significant difference between the two groups (P = 0.203, Fisher's exact test). The detected mutations included G118R, L74M, E157Q, S230R, T66TA, S153F, and E157Q. A total of 15 transmission clusters were identified, with a network entry rate of 32.00% (40/125). Subtype G exhibited a significantly higher entry rate of 90.0% (9/10, 95% CI: 55.50-99.75%) compared to 26.96% (31/115, 95% CI:19.11-36.03%) for other subtypes combined (Fisher's exact test, P<0.001). Conclusion: This study indicates that resistance to INSTI after treatment failure is rare, with BIC exhibiting a higher genetic barrier than DTG. Nonetheless, given the potential for transmission of resistant variants, ongoing surveillance remains essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.